Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) delivers targeted therapies for central nervous system disorders through its precision medicine approach. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely press releases covering trial results, platform innovations (including Cerebrum™ small molecule and Solidus™ ASO technologies), and progress in treating epilepsy, depression, and essential tremor. Our curated collection ensures you stay informed about PRAX's advancements in addressing neuronal excitation-inhibition imbalances through genetic insights.
Discover updates categorized by clinical trial phases, collaborative research initiatives, and therapeutic area developments. Bookmark this page for streamlined access to Praxis' latest scientific achievements and corporate announcements in the CNS biopharmaceutical space.
Praxis Precision Medicines, Inc. will release its first quarter 2024 financial results on May 13, 2024. The company focuses on developing therapies for CNS disorders related to neuronal excitation-inhibition imbalance.
Praxis Precision Medicines, Inc. announced the granting of non-qualified stock options and restricted stock units to six new non-executive employees under the 2024 Inducement Plan. The options have an exercise price of $55.16 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments. This move aims to attract and retain top talent for the company.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
